"Chemoradiotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Treatment that combines chemotherapy with radiotherapy.
| Descriptor ID |
D059248
|
| MeSH Number(s) |
E02.186.079 E02.319.164 E02.815.160
|
| Concept/Terms |
Chemoradiotherapy- Chemoradiotherapy
- Chemoradiotherapies
- Radiochemotherapy
- Radiochemotherapies
Concurrent Chemoradiotherapy- Concurrent Chemoradiotherapy
- Chemoradiotherapies, Concurrent
- Chemoradiotherapy, Concurrent
- Concurrent Chemoradiotherapies
- Synchronous Chemoradiotherapy
- Chemoradiotherapies, Synchronous
- Chemoradiotherapy, Synchronous
- Synchronous Chemoradiotherapies
- Concurrent Radiochemotherapy
- Concurrent Radiochemotherapies
- Radiochemotherapies, Concurrent
- Radiochemotherapy, Concurrent
- Concomitant Chemoradiotherapy
- Chemoradiotherapies, Concomitant
- Chemoradiotherapy, Concomitant
- Concomitant Chemoradiotherapies
- Concomitant Radiochemotherapy
- Concomitant Radiochemotherapies
- Radiochemotherapies, Concomitant
- Radiochemotherapy, Concomitant
|
Below are MeSH descriptors whose meaning is more general than "Chemoradiotherapy".
Below are MeSH descriptors whose meaning is more specific than "Chemoradiotherapy".
This graph shows the total number of publications written about "Chemoradiotherapy" by people in this website by year, and whether "Chemoradiotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2011 | 5 | 3 | 8 |
| 2012 | 5 | 6 | 11 |
| 2013 | 12 | 4 | 16 |
| 2014 | 7 | 3 | 10 |
| 2015 | 8 | 5 | 13 |
| 2016 | 8 | 9 | 17 |
| 2017 | 5 | 14 | 19 |
| 2018 | 5 | 10 | 15 |
| 2019 | 4 | 5 | 9 |
| 2020 | 9 | 4 | 13 |
| 2021 | 3 | 10 | 13 |
| 2022 | 1 | 8 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemoradiotherapy" by people in Profiles.
-
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. J Thorac Oncol. 2023 02; 18(2):181-193.
-
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. J Thorac Oncol. 2022 12; 17(12):1415-1427.
-
Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol. 2022 08 10; 40(23):2546-2556.
-
Decreased overall survival in patients with locally advanced head and neck cancer receiving definitive radiotherapy and concurrent cetuximab: National Cancer Database analysis. Head Neck. 2022 07; 44(7):1528-1544.
-
Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III?study design. Future Oncol. 2022 May; 18(14):1669-1678.
-
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 04 20; 40(12):1301-1311.
-
Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC). Am J Clin Oncol. 2022 02 01; 45(2):49-54.
-
Impact of the viability assessment of lateral lymph node metastasis in rectal cancer after neoadjuvant chemoradiotherapy. Int J Colorectal Dis. 2022 Feb; 37(2):467-473.
-
Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17.
-
Radiotherapy and immunotherapy: open questions and future strategies. Trends Cancer. 2022 01; 8(1):9-20.